KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 73 filers reported holding KINNATE BIOPHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $147,251 | -39.4% | 105,179 | +31.2% | 0.05% | -30.3% |
| Q2 2023 | $242,942 | -52.0% | 80,179 | -1.0% | 0.07% | -56.6% |
| Q1 2023 | $506,300 | +16.9% | 81,008 | +14.1% | 0.15% | +24.6% |
| Q4 2022 | $433,149 | -53.6% | 71,008 | -9.1% | 0.12% | -51.4% |
| Q3 2022 | $933,000 | -67.0% | 78,074 | -65.2% | 0.25% | -67.4% |
| Q2 2022 | $2,830,000 | +69.7% | 224,451 | +51.5% | 0.77% | +77.2% |
| Q1 2022 | $1,668,000 | -11.6% | 148,151 | +39.2% | 0.44% | -8.2% |
| Q4 2021 | $1,886,000 | -23.1% | 106,453 | 0.0% | 0.47% | -27.1% |
| Q3 2021 | $2,451,000 | +93.4% | 106,453 | +95.6% | 0.65% | +145.3% |
| Q2 2021 | $1,267,000 | -23.2% | 54,415 | +2.8% | 0.26% | -32.2% |
| Q1 2021 | $1,649,000 | -39.2% | 52,915 | -22.3% | 0.39% | -51.5% |
| Q4 2020 | $2,710,000 | – | 68,121 | – | 0.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |